Forge Therapeutics Excites Big Guns In Antibiotic World
Emerging Company Profile: Forge Therapeutics, which licensed intellectual property from the University of California San Diego in 2015, is aiming to have developed a novel class of antibiotic to treat Gram-negative superbugs, with its first drug candidate entering clinical development in 2020. The company has just announced an expanded research and discovery pact with Evotec in the UK, and boasts an impressive line-up of scientific advisors.
You may also be interested in...
Deal Watch: Coronavirus Collaborations Reflect Industry’s Full Press Pandemic Response
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
Top-Selling Drugs 2022: Strong Growth In Blockbuster Ranks
COVID-19 products contributed almost a third to the global revenues from the top 20 best-selling drugs in 2022. However, strong growth was also seen for drugs across categories from immunology and cancer to HIV and cardiometabolic.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 10: Diversity, Equity And Inclusion
The acceleration of efforts to increase diversity among clinical trial subjects is expected to continue in 2023. Furthermore, many executives hope for greater inclusivity within companies, from new recruits to leadership.